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Abstract
Injectable vitamin D agents are commonly used to manage secondary hyperparathyroidism in 
dialysis patients. Yet, there are few data documenting the trends and geographic variations in the 
use of these agents in large, representative samples. We sought to describe patterns and variations 
in the use of vitamin D formulations (calcitriol, paricalcitol, and doxercalciferol) in hemodialysis 
patients. We studied patients in the United States Renal Data System between January1999 and 
December 2008 with Medicare as a primary payer. Annual percentages of patients treated with 
each type of formulation were tabulated by race, sex, and age at dialysis initiation. The 
geographical distribution of vitamin D dose per patient was mapped at the state level. Intravenous 
vitamin D use has increased sharply from 1999 to 2008 with 83.9% of patients treated with any 
vitamin D formulation in 2008. The use of calcitriol has declined since 1999, going from being 
administered in 58.6% of patients in 1999 to 1.8% in 2008. Paricalcitol was found to be the 
overwhelmingly preferred formulation during the study years. In 2008, the average dose among 
black patients was 84% greater than among white patients (136 mcg vs. 73.6 mcg). Higher doses 
of vitamin D were administered to patients in the southern region of the country. Vitamin D use 
has increased and parallels the rise in use of paricalcitol and doxercalciferol. Given the variations 
in use and known pharmacologic differences in vitamin D formulations, future research should 
focus on whether the formulations differentially affect patient outcomes.
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Secondary hyperparathyroidism (SHPT), characterized by elevated parathyroid hormone 
(PTH) levels, is a common complication found in hemodialysis patients.1 SHPT-induced 
changes in bone histology coupled with increased serum phosphorous and calcium levels 
have all been implicated as factors partially responsible for the increased morbidity and 
mortality observed in hemodialysis patients in comparison with individuals in the general 
population.2 The suppression of PTH levels through activated vitamin D therapy has been 
central to the treatment of SHPT in the dialysis population.1 Vitamin D therapy helps to 
maintain appropriate mineral metabolism, prevents bone disease, and minimizes loss of bone 
strength and fractures.3 Additionally, treatments for SHPT aim to prevent the numerous 
extra skeletal complications that may be associated with the high cardiovascular morbidity 
observed in end-stage renal disease (ESRD).
Currently, there are three commonly prescribed intravenous (IV) vitamin D therapies: 
calcitriol (1α,25-dihydroxyvitamin D3; Calcijex, Abbott Laboratories, North Chicago, IL, 
USA), paricalcitol (19-nor-1α,25-dihydroxyvitamin D2; Zemplar, Abbott Laboratories), and 
doxercalciferol (1α-hydroxyvitamin D2; Hectorol, Genzyme, Cambridge, MA, USA). There 
have been several studies describing patient-level predictors of vitamin D use in the dialysis 
population.4,5 These studies have found that dialysis patients who administered vitamin D 
were generally younger, were more likely to be black, and were more likely to have a fistula 
or graft.6 However, to date, studies reporting temporal trends in the use of IV vitamin D 
formulations have been conducted using small sample sizes, and none has graphically 
depicted geographic patterns of vitamin D use.7
In this study, we address this gap in the literature. Using data on US hemodialysis patients in 
Medicare’s ESRD program between 1 January 1999 and 31 December 2008, we report 




Data were extracted from the United States Renal Data System (USRDS). The USRDS 
contains detailed demographic and treatment information including the date of dialysis 
initiation for all patients beginning renal replacement therapy. All Medicare Part A and B 
claims were also included within the USRDS data set, including diagnosis and procedure 
codes for inpatient and outpatient visits.
Study Design and Patient Population
The study cohort consisted of prevalent hemodialysis patients of all ages between 1 January 
1999 and 31 December 2008. Patients were required to have Medicare as a primary payer 
for the duration of the follow-up period. Patients were eligible if hemodialysis was their 
initial mode of renal replacement therapy, and no adjustments were made to account for any 
later switches in treatment modality.
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Patterns of Vitamin D Use Assessment
Medicare Part A outpatient revenue files were used to identify IV vitamin D administered to 
hemodialysis patients. Healthcare Common Procedure Coding System (HCPCS) J-codes 
were used to identify vitamin D claims. Calcitriol use was identified using HCPCS codes 
J0635 (1 mcg) and J0636 (0.1 mcg). The codes J2500 (5 mcg) and J2501 (1 mcg) were used 
to identify paricalcitol use, and the code J1270 (1 mcg) was used to identify doxercalciferol 
use.
The mean annual vitamin D dose of each formulation per patient was computed for all study 
years for all patients and by race. A patient was defined as a vitamin D user during each 
study year if they were administered any dose of any of the three formulations. Variations in 
IV vitamin D use were assessed according to the annual percentage of patients treated with 
any vitamin D formulation by race, sex, and age at dialysis initiation (<18, 18–34, 35–44, 
45–54, 55–64, and ≥65 years). Race was classified as “white” or “black.”
To obtain the total and mean annual doses of vitamin D administered to each patient, annual 
doses of paricalcitol and doxercalciferol administered to each patient were converted to 
calcitriol-equivalent doses according to conversion ratios derived by St. Peter and colleagues 
(4.6:1 for paricalcitol:calcitriol and 3.1:1 for doxercalciferol:calcitriol).8 Since the 
administration of vitamin D to hemodialysis patients may not be accurately captured during 
hospital stays, annual vitamin D doses during the total number of outpatient days during the 
year were tabulated. The number of hospitalization days per year per patient remained 
constant from 1999 to 2008; therefore, restricting our exposure period to only outpatient 
days should not impact our results.
All statistical analyses were performed using SAS version 9.2 (SAS Institute, Inc., Cary, 
NC, USA). Descriptive statistics were used to tabulate mean annual doses of vitamin D and 
the percentage of vitamin D users per year overall and by subgroup. Geographical trends in 
vitamin D were described using the SAS PROC GMAP option to depict the mean vitamin D 
dose administered per patient at the state level. The PROC GMAP feature allows SAS users 
to graph two- or three-dimensional color maps by combining map and response data.9 
Geographical trends were presented among the whole eligible patient population of blacks 
and whites and also among only black patients to elucidate any racial influences on 
geographical variations in annual vitamin D dose per patient. Ordinary least squares (OLS) 
regression was used to assess the predictors of annual vitamin D dose per patient in 2008. 
Logistic regression analysis was used to assess the predictors of vitamin D use in 2008. Age, 
sex, race, and cause of ESRD were adjusted for as potential confounders in both models. 
The following comorbidities were included in the models as dichotomous variables: 
coronary artery disease, congestive heart failure, cerebrovascular accident/transient ischemic 
attack, peripheral vascular disease, other cardiac disease, liver disease, chronic obstructive 
pulmonary disease, gastrointestinal tract bleeding, dysrhythmia, cancer, and diabetes 
mellitus.
This study was exempt from review by the University of North Carolina at Chapel Hill 
Institutional Review Board.
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Table 1 describes the baseline characteristics of the prevalent hemodialysis cohort in years 
1999–2008. The study population consisted of 225,022 patients in 1999 and 315,608 
patients in 2008. The mean patient age was consistently 59 years old (SD = 17) throughout 
the 10-year study period. There were 52.0% of males in 1999, increasing to 54.3% in 2008. 
The percentage of white and black patients remained consistent during the 10-year study 
period at approximately 57% and 37%, respectively. Diabetes as the primary cause of renal 
failure increased from 41.1% of the study population in 1999 to 44.7% in 2008, whereas 
glomerulonephritis as the primary cause of renal failure decreased from 14.1% of patients to 
11.4%. Approximately 29% of all patients reported hypertension as the primary cause of 
renal failure in all study years.
Figure 1 depicts the annual percentage of patients treated with each vitamin D formulation 
from January 1999 to December 2008. IV vitamin D use has increased sharply from 1999 to 
2008 with 58.6% of patients treated with any vitamin D formulation in 1999 to 
approximately 84% treated with any vitamin D formulation in 2008. The use of calcitriol has 
declined since 1999, going from being administered to 58.6% of patients in 1999 to 1.8% in 
2008. Paricalcitol was the overwhelmingly preferred formulation. Between 2000 and 2008, 
the annual percentage of patients administered paricalcitol increased from 35.6% to 66.3%. 
Paricalcitol use peaked at 65.2% of patients in 2003, declined slightly to 59.7% of patients, 
then again increased to 66.3% in 2008. Doxercalciferol use in the hemodialysis cohort began 
in 2002 with 10% of patients administered the drug, steadily increased to a peak of 28.8% of 
patients treated with doxercalciferol in 2006, and has begun to slightly decline to 23.7% of 
patients treated in 2008.
The annual percentage of patients treated with vitamin D by race is presented in Figure 2. In 
1999, approximately 26% of the total patient population was black vitamin D users, whereas 
29% was white vitamin D users. Both the percentage of white and black vitamin D users 
increased steadily from 1999 to 2008. Approximately 34% of the prevalent patient 
population was black vitamin D users in 2008 and the percentage of white vitamin D users 
increased to 45%.
Racial variations in vitamin D dose are shown in Table 2. In 1999, when calcitriol was the 
only IV formulation administered, white patients received an average dose of 47.7 mcg, 
whereas black patients received approximately 46% more vitamin D at an average dose of 
70 mcg. Black patients were administered nearly twice as much vitamin D than white 
patients annually between 2000 and 2006. In 2007, black patients received 88% more 
vitamin D than white patients (average dose, 129.7 mcg for blacks vs. 69.l mcg for whites), 
and in 2008, black patients received 84% more vitamin D than white patients (average dose, 
136 mcg for blacks vs. 73.6 mcg for whites).
Figure 3 depicts the annual percentage of patients administered vitamin D by sex. In 1999, 
approximately 30% of all patients were male vitamin D users, and in 2008, about 45% of all 
patients were male vitamin D users.
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Approximately 1% of all patients were vitamin D users under 18 years old and this remained 
constant between 1999 and 2008. Approximately 5% and 7% of all patients were between 
18 and 34 years old in 1999 and 2008, respectively. Approximately 12% of patients were 
vitamin D users between 55 and 64 years old in 1999 and increased to 18% in 2008, whereas 
approximately 25% of patients were vitamin D users at least 65 years old in 1999, increasing 
to 33% in 2008.
Annual trends in the mean dose administered of each vitamin D formulation among the 
users of that respective formulation are listed in Table 3. The average annual calcitriol dose 
per calcitriol user has declined over the past decade, reflecting the decreased administration 
of the formulation. In 1999, on average, 94.9 mcg (SD = 3458) of calcitriol was 
administered per calcitriol user. In 2008, the average calcitriol dose per calcitriol user was 
69.8 mcg (SD = 87.6). With regards to paricalcitol, the average annual dose per paricalcitol 
user increased from 7.97mcg (SD = 4.49) in 1999 to 105 mcg (SD = 118) in 2008. The 
average annual dose of doxercalciferol per doxercalciferol user also increased steadily from 
1999 to 2008.
Geographical trends in the average annual dose of vitamin D administered per patient among 
all eligible patients are depicted in Figure 4. In 1999, only seven states had a mean annual 
dose of vitamin D per patient greater than 60 mcg (South Dakota, Minnesota, Iowa, 
Kentucky, Delaware, Mississippi, and South Carolina) with patients administered the highest 
vitamin D doses in South Dakota and Kentucky. In contrast, 18 states had an average annual 
vitamin D dose per patient greater than 60 mcg in 2000 with four of the six states with 
average doses between 80 mcg and 100 mcg clustered in the south (Louisiana, Mississippi, 
Alabama, and South Carolina). The highest doses of vitamin D per patient were 
administered in California, northeast, and southern region of the country in 2002. In 2002, 
Delaware, South Carolina, Mississippi, and Kansas had an average annual vitamin D dose 
per patient greater than 100 mcg. In 2008, 14 states had a mean yearly vitamin D dose per 
patient greater than 100 mcg (Connecticut, New Jersey, Delaware, Maryland, Virginia, North 
Carolina, South Carolina, Tennessee, Georgia, Alabama, Mississippi, Louisiana, Texas, and 
Illinois). Figure 5 depicts geographical trends in the average annual vitamin D dose per 
patient among only black patients. When the population was restricted to only black 
patients, in 2008, only five states (Idaho, Montana, Utah, Colorado, and South Dakota) had 
an average annual vitamin D dose per patient less than 100 mcg.
Results from a multivariable logistic regression model predicting vitamin D use (yes/no) and 
a multiple regression model predicting annual vitamin D dose (mcg) per patient in 2008 are 
shown in Table 4. For black patients, the odds of being administered vitamin D are 2.38 
times greater than the odds for white patients being administered vitamin D. Male sex, black 
race, and increasing vintage were associated with a significant increase in annual vitamin D 
dose per patient.
DISCUSSION
This study investigated secular trends and variations in the administration of specific vitamin 
D analogs in hemodialysis patients. The data suggest that there have been a substantial 
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increase in the use of vitamin D among hemodialysis patients in the United States between 
1999 and 2008. As of 2008, approximately 84% of the USRDS population used IV vitamin 
D. With regards to formulation-specific patterns of utilization, calcitriol use has declined 
sharply since 1999. In contrast, paricalcitol was the most frequently administered 
formulation in the United States with 66.3% of patients treated with the analog in 2008. 
Doxercalciferol use declined steadily since its peak usage of 28.8% of patients in 2006.
The study presented herein is unique in its use of a relatively large population of over 
300,000 patients in the most recent years of available data until 2008. It should be noted that 
the Dialysis Outcomes and Practice Patterns Study (DOPPS), a prospective cohort study of 
hemodialysis patients in 19 countries, released recent data regarding trends in IV vitamin D 
formulation use and dose in the United States.7 Unlike this study, however, DOPPS 
investigators based their observations on a relatively small sample of less than 4000 US 
dialysis patients. Consistent with the results of this study, the DOPPS study reported that in 
August 2010, 85.3% of the sample used only paricalcitol, 13.6% used only doxercalciferol, 
and 1.0% used only calcitriol. However, in December 2011, the percentage of patients using 
only paricalcitol decreased to 55.5%, doxercalciferol users increased to 44.2%, and calcitriol 
users was 0.1%.
Clinical differences between the three formulations may explain the changes over time in IV 
vitamin D formulation choice. The first available vitamin D analog, calcitriol, can effectively 
lower serum PTH levels.10 However, calcitriol administered in dialysis patients has been 
associated with elevated serum calcium and phosphorous concentrations.11 The risk of 
hypercalcemia may increase when calcitriol is used simultaneously with calcium-based 
phosphorous binders or dialysate with high calcium concentrations.10 The vitamin D2 
analogs, paricalcitol and doxercalciferol, are also considered as mainstream therapy among 
dialysis patients.10 Both vitamin D2 analogs, like calcitriol, can effectively lower PTH levels 
but with a smaller effect on serum calcium and phosphorous concentrations compared to 
calcitriol.10 Several studies have demonstrated equivalent or even superior PTH level 
suppression with the use of either paricalcitol or doxercalciferol compared to calcitriol.12
The preponderance of paricalcitol use within the hemodialysis population as demonstrated 
by the data, however, does not decrease the need to explore the comparative effectiveness of 
IV vitamin D agents. A meta-analysis of randomized controlled trials of chronic kidney 
disease patients demonstrated both potentially beneficial and detrimental effects of vitamin 
D compounds such as paricalcitol and doxercalciferol introduced into the market after 
calcitriol. Paricalcitol and doxercalciferol vitamin D compounds were shown to significantly 
reduce PTH levels by about 11 pmol/L but they also simultaneously increase phosphorous 
levels.12 Reduced PTH levels may correspond to a decrease in patient mortality risk by 
approximately 5% to 10% over a 3-year span but the increase in phosphorous concentrations 
may increase mortality by an equivalent amount.12
The most striking differences in vitamin D use were found in comparisons of annual vitamin 
D dose per patient between black and white patients. Although the percentage of black 
patients receiving vitamin D was less than the percentage of white patients over the past 
decade, black patients have continued to receive nearly twice as much of the drug in 
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comparison with whites. This greater use is possibly a result of pervasive vitamin D 
deficiency associated with individuals with darker pigmented skin. In the general population, 
90% of Mexican-Americans and nearly all non-Hispanic blacks (97%) currently suffer from 
vitamin D deficiency.13 Additionally, black hemodialysis patients generally have higher 
intact PTH levels in comparison with other races.14 Gupta and colleagues reported an 
average PTH level of 641.7 in black and 346.0 in white dialysis patients.15 Therefore, the 
greater severity of SHPT among black patients may be associated with the greater vitamin D 
dose administered to these individuals in comparison with white patients.
Our findings are consistent with the finding by Kalantar-Zadeh and colleagues 
demonstrating that African-Americans had twice the odds of receiving a higher dose of 
paricalcitol (>10 mcg/week) than other races in a study of ESRD patients in a large dialysis 
organization.16 In addition, the greater administration of IV vitamin D to black dialysis 
patients is reflected in cost figures from the 2011 USRDS Annual Data Report. In 2008, IV 
vitamin D costs were 78% greater for black patients compared to white patients within the 
prevalent dialysis population with vitamin D costs reaching $1,824 per patient per year for 
blacks.17
Moreover, since 1999, higher doses of vitamin D per patient were found in the southern 
region of the United States in states such as Mississippi, Louisiana, and Alabama. St. Peter 
and colleagues have also reported geographic variations in injectable drug use among the 
dialysis population.18 For instance, the authors found the greatest use of IV iron in Alaska 
and eastern Texas, whereas the lowest percentages of IV iron were found in the central 
region of the country.18 Patient-, facility-, and policy-level factors contributing to the 
geographic differences in injectable drug administration to hemodialysis patients merit 
further investigation. More research is needed to investigate how the greater administration 
of vitamin D doses to black patients or individuals with higher body mass indexes impacts 
the observed regional differences in vitamin D administration.
The study has important limitations. Since Medicare Part A data within the USRDS are 
collected primarily for administrative purposes, we cannot know whether the amount of 
vitamin D dose billed actually reflects the amount of vitamin D received for each patient. 
The dosage reflected in vials billed for a particular formulation may not accurately capture 
partial doses administered. In addition, administration of vitamin D is guided primarily by 
patient serum PTH levels, a variable not available in the USRDS. Our multivariable analyses 
assessing predictors of vitamin D use and annual vitamin D dose per patient were likely 
highly confounded, given that we did not have access to PTH levels.
Our data suggest that the frequency and doses of vitamin D are increasing. Patterns of 
prevalent vitamin D use at different times over a decade show that while use of vitamin D in 
general has increased, both calcitriol use and doxercalciferol use have decreased while 
paricalcitol emerged, at least temporarily, as the dominant formulation. Recent controversy 
regarding the therapeutic effects of vitamin D in ESRD has sparked interest in the 
comparative effectiveness and safety of vitamin D formulations. Given the increase in dose 
and variation in use of these formulations, more research is needed to investigate the 
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comparative differences in patient health outcomes resulting from the use of paricalcitol 
versus doxercalciferol versus calcitriol.
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Annual percentage of patients treated with IV vitamin D by formulation.
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Annual percentage of vitamin D users by race.
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Annual percentage of vitamin D users by sex.
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Annual vitamin D dose per patient by state among both white and black patients (1999–
2008).
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Annual vitamin D dose per patient by state among only black patients (1999–2008).
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Table 2
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Table 3
Mean annual IV vitamin D dose (mcg) administered per patient by formulation.
Year
Calcitriol Paricalcitol Doxercalciferol
Mean dose (SD) Mean dose (SD) Mean dose (SD)
1999 94.9 (3458)   7.97 (4.49)     0.0 (0.0)
2000 74.8 (320.3)   79.5 (431)     0.0 (0.0)
2001 70.6 (216.0)   99.4 (389)     0.0 (0.1)
2002 74.3 (150.3)    108 (552)     6.3 (42.9)
2003 81.2 (1802)   90.6 (144)     8.4 (32.1)
2004 72.6 (146.1)   91.6 (124.8)   89.3 (158)
2005 73.4 (93.2)   95.8 (195)   95.5 (85.7)
2006 78.4 (92.7)   97.0 (110) 103.0 (137)
2007 78.2 (97.2)   96.6 (103) 107.0 (120)
2008 69.8 (87.6) 105.0 (118) 112.0 (111)
Note: SD, standard deviation.
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Table 4
Logistic regression model predicting vitamin D use (yes/no) and multiple regression model predicting annual 
vitamin D dose (mcg) per patient in 2008.
Vitamin D use Annual vitamin D dose
(OR) 95% CI Parameter estimate p-Value
Age (reference group is age greater than 65 years)
 0–18 years 0.59 0.54–0.65 −25.0 <0.0001
 18–64 years 1.24 1.21–1.27   12.9 <0.0001
Male sex 0.97 0.95–0.99     2.90 <0.0001
Black race 2.38 2.32–2.43   52.7 <0.0001
Cause of ESRD (reference group is diabetes mellitus)
 Hypertension 0.94 0.91–0.96   −2.36 0.0002
 GN 0.79 0.77–0.82   −8.81 <0.0001
 Other 0.71 0.69–0.73   −7.71 <0.0001
Vintage (years) 1.07 1.06–1.07     4.02 <0.0001
CAD 1.08 1.06–1.11     0.44   0.34
CHF 0.92 0.90–0.94   −3.21 <0.0001
TIA 0.88 0.86–0.90   −6.75 <0.0001
PVD 1.02 1.00–1.04     0.34   0.0021
Other cardiac disease 1.04 1.02–1.06     1.34   0.016
Liver disease 0.88 0.85–0.91 −10.7 <0.0001
COPD 0.90 0.88–0.92   −1.35 0.0037
Gastrointestinal bleed 0.81 0.79–0.84 −11.1 <0.0001
Dysrhythmia 0.87 0.85–0.89 −11.0 <0.0001
Cancer 0.82 0.80–0.84     −8.24 <0.0001
Diabetes mellitus 0.97 0.94–0.99     −0.73   0.16
Notes: OR, odds ratio; CI, confidence interval; ESRD, end-stage renal disease; GN, glomerulonephritis; CAD, coronary artery disease; CHF, 
congestive heart failure; TIA, transient ischemic attack; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disorder.
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